Clinical trial

Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer

NCT05329532

Study summary

ClinicalTrials.gov

Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1, PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

BIOLOGICAL · Unmapped registry intervention Modi-1 Moditope Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention Pembrolizumab Find medicine records · Find other trials using this name

DEVICE · Unmapped registry intervention MicronJet600™ microneedle device (NanoPass) Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2022-04-07

PhasePHASE1 / PHASE2

Conditions

Triple Negative Breast Cancercandidate · MONDO: triple-negative breast carcinoma

Renal Cell Cancerverified · MONDO: renal cell adenocarcinoma

High Grade Ovarian Serous Adenocarcinomaunresolved

Squamous Cell Carcinoma of the Head and Neckverified · MONDO: head and neck squamous cell carcinoma

Interventions

Modi-1 ModitopeBIOLOGICAL

PembrolizumabBIOLOGICAL

MicronJet600™ microneedle device (NanoPass)DEVICE

Sponsors & collaborators

Scancell Ltdlead sponsor

Mapped research locations

CambridgeUnited Kingdom1 LiverpoolUnited Kingdom1 BelfastUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05329532 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.